EUVIMEDEUVIMED entdecken
Open Access

Cost‐Effectiveness of Coronary Artery Calcium Scoring for Cardiovascular Disease Prevention in Diabetes: An Analysis From MESA

Bart S Ferket iD, M G Myriam Hunink iD, Umesh Masharani iD, Wendy Max iD, Joseph Yeboah iD, Kirsten E Fleischmann iD

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.041543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Bart S Ferket und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Healthcare Delivery Science, Department of Population Health Science and Policy Icahn School of Medicine at Mount Sinai New York NY USA. Hauptthemen laut MEDLINE: Coronary Artery Disease, Vascular Calcification, Diabetes Mellitus, Coronary Vessels. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Coronary artery calcium scoring ( CACS ) by computed tomography could enhance risk assessment and decision making for preventive medication in patients with diabetes. We performed a microsimulation study to compare costs and health outcomes of guideline‐based periodic cardiovascular risk assessment with and without CACS .

Methods

We modeled various US guideline‐based preventive approaches based on periodically assessed 10‐year risk by pooled cohort equations with and without CACS. We predicted cumulative costs and quality‐adjusted life years (QALYs) until age 100 years from the US health care sector perspective in MESA (Multi‐Ethnic Study of Atherosclerosis) participants aged 45 to 84 years with diabetes (n=853), who were weighted to represent the US general patient population. Probabilistic and deterministic sensitivity analyses were performed to address uncertainty.

Results

Initiating high‐intensity statins regardless of risk and low‐dose aspirin if 10‐year risk ≥10% led to the largest QALY gains with incremental cost‐effectiveness ratios of $35 000 to $40 000/QALY. When omitting such universal approaches, allocating high‐intensity statins and low‐dose aspirin if CACS ≥100 led to incremental cost‐effectiveness ratios around $50 000/QALY. Ranking of strategies by cost‐effectiveness was generally robust against parameter uncertainty. The incremental cost‐effectiveness ratio of the CACS ≥100 strategy fell below $50 000/QALY if the fee of CACS fell below $75 or when statin continuation was assumed to significantly improve with nonzero CAC scores.

Conclusions

Broadening the use of high‐intensity statins and low‐dose aspirin in patients aged 45 to 84 years with diabetes can be considered cost‐effective. If broad‐scale use of intensive preventive treatment is either not feasible or not desired, then CACS may be cost‐effective in refining preventive treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseVascular CalcificationDiabetes MellitusCoronary VesselsCoronary AngiographyComputed Tomography AngiographyCardiovascular DiseasesHumansCost-Benefit AnalysisAgedMiddle AgedMaleFemaleAged, 80 and overQuality-Adjusted Life YearsRisk AssessmentUnited StatesHydroxymethylglutaryl-CoA Reductase InhibitorsAspirin

Stichwörter der Autor:innen

coronary calciumcost‐effectivenessdiabetespreventionrisk assessment

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsAspirin

Autor:innen und Institutionen

  • Institute for Healthcare Delivery Science, Department of Population Health Science and Policy Icahn School of Medicine at Mount Sinai New York NY USA.
  • Department of Epidemiology and Radiology Erasmus MC Rotterdam The Netherlands.
  • Center for Health Decision Sciences Harvard TH Chan School of Public Health Boston MA USA.
  • Department of Medicine University of California San Francisco CA USA.
  • Institute for Health & Aging and Department of Social and Behavioral Sciences University of California San Francisco CA USA.
  • Heart and Vascular Center of Excellence Wake Forest Baptist Health Winston Salem NC USA.

ORCID-Profile: Bart S Ferket, M G Myriam Hunink, Umesh Masharani, Wendy Max, Joseph Yeboah, Kirsten E Fleischmann

Förderung

  • NHLBI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Ferket, B. S., Hunink, M. G. M., Masharani, U., Max, W., Yeboah, J., & Fleischmann, K. E. (2025). Cost‐Effectiveness of Coronary Artery Calcium Scoring for Cardiovascular Disease Prevention in Diabetes: An Analysis From MESA. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.041543

Vancouver

Ferket BS, Hunink MGM, Masharani U, Max W, Yeboah J, Fleischmann KE. Cost‐Effectiveness of Coronary Artery Calcium Scoring for Cardiovascular Disease Prevention in Diabetes: An Analysis From MESA. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.041543

BibTeX
@article{Ferket2025,
  author = {Ferket, Bart S and Hunink, M G Myriam and Masharani, Umesh and Max, Wendy and Yeboah, Joseph and Fleischmann, Kirsten E},
  title = {Cost‐Effectiveness of Coronary Artery Calcium Scoring for Cardiovascular Disease Prevention in Diabetes: An Analysis From MESA},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.041543}
}
Kostenlos starten →